Midas Group Inc. (MDS) - NYSE
MDS is defunct.
  • Aug. 28, 2013, 7:37 AM
    • Astex Pharmaceuticals' (ASTX) SGI-110 "showed clear activity in patients with acute myeloid leukemia" in Phase II testing.
    • The overall remission rate in 67 subjects was 25%.
    • However, no results were provided for patients with Myelodysplastic syndromes (MDS), a group of blood and bone marrow disorders, who were also part of the trial.
    • Shares +12.2%.
    | Aug. 28, 2013, 7:37 AM
  • Mar. 13, 2012, 9:00 AM

    Premarket gainers: OMER +31%. MDS +28%. WOLF +26%. UTSI +16%. TTM +3%.
    Losers: SB -10%. COOL -8%. YOKU -5%. URBN -4%. MWE -3%.

    | Mar. 13, 2012, 9:00 AM
  • Aug. 12, 2011, 8:54 AM

    Midas (MDS) +23.9% premarket after the auto repair and services company announced after yesterday's close that it is exploring strategic alternatives including a possible sale, merger or other business combination.

    | Aug. 12, 2011, 8:54 AM
Company Description
Currently, there's no company description for MDS.
Sector: Services
Industry: Specialty Retail, Other
Country: United States